VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NBIX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NBIXNeurocrine Biosciences, Inc.
$165.92$16.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. NBIX
  4. Financial Ratios

Neurocrine Biosciences, Inc. (NBIX) Financial Ratios

Latest Ratios: P/E Ratio 24.8x · EV/EBITDA 17.0x · ROE 16.4%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

NBIX Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$16.7B$14.5B$14.2B$13.3B$11.8B$8.3B$9.4B$10.3B$6.8B$6.8B$3.4B
Enterprise Value$16.4B$14.2B$14.4B$13.5B$11.8B$8.4B$9.6B$10.7B$7.1B$6.9B$3.3B
P/E Ratio →24.8530.3741.4953.3476.5692.5823.04275.62324.59——
P/S Ratio4.515.086.017.057.937.368.9613.0615.1042.29223.72
P/B Ratio5.234.475.475.966.926.078.3216.1614.1718.3710.66
P/FCF16.0519.4225.4036.8036.5835.7743.0877.7888.94——
P/OCF21.3218.5723.7734.1334.8032.5141.0270.0067.18——

P/E links to full P/E history page with 30-year chart

NBIX EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—4.986.107.157.937.449.1813.5415.6543.00218.17
EV / EBITDA16.9821.9324.0649.5444.6474.4155.94133.92173.02——
EV / EBIT26.4722.3723.4734.1653.4566.3368.81135.97134.98——
EV / FCF—19.0225.8037.2936.5836.2044.1180.6892.16——

NBIX Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin98.2%98.2%98.6%97.9%98.4%98.7%99.0%99.1%98.9%99.2%100.0%
Operating Margin21.6%21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%
Net Profit Margin16.7%16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE16.4%16.4%14.2%12.7%10.0%7.2%46.2%6.6%5.0%-41.5%-38.2%
ROA11.5%11.5%9.8%8.9%7.0%4.7%26.8%3.2%2.3%-24.1%-33.6%
ROIC16.1%16.1%16.4%9.1%11.7%5.4%10.3%6.2%4.5%-27.4%-38.0%
ROCE17.4%17.4%19.6%11.3%13.6%6.1%14.2%8.8%4.4%-23.9%-37.6%

NBIX Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.130.130.180.190.150.320.370.780.810.99—
Debt / EBITDA0.640.640.761.570.993.882.406.229.52——
Net Debt / Equity—-0.090.090.080.000.070.200.600.510.31-0.26
Net Debt / EBITDA-0.46-0.460.370.650.000.881.314.816.05——
Debt / FCF—-0.400.400.490.000.431.032.903.22——
Interest Coverage——4.8485.8331.134.934.252.451.71-6.30—

Net cash position: cash ($713M) exceeds total debt ($415M)

NBIX Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.393.393.402.452.703.965.451.478.3610.2010.21
Quick Ratio3.303.303.282.402.643.835.301.448.2410.1810.21
Cash Ratio1.991.992.121.581.842.894.291.197.389.4810.11
Asset Turnover—0.620.630.580.630.550.600.600.450.200.04
Inventory Turnover0.760.760.591.040.660.470.360.430.451.22—
Days Sales Outstanding—87.6474.2584.9785.8159.7354.8358.6346.4470.29—

NBIX Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield4.0%3.3%2.4%1.9%1.3%1.1%4.3%0.4%0.3%——
FCF Yield6.2%5.2%3.9%2.7%2.7%2.8%2.3%1.3%1.1%——
Buyback Yield1.0%1.2%2.1%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield1.0%1.2%2.1%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$103M$104M$101M$99M$98M$98M$96M$95M$88M$87M

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowImproving
Top Statement Risk

Margin volatility and valuation premium

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Pricing in Sustained Growth

Based on the supplied valuation data, NBIX trades at a trailing P/E of 34.21 and forward P/E of 22.39, with a P/FCF of 21.46, a premium to the peer group where profitable comparables such as INVA trade near 5.83x earnings.

The compression from 34.21x trailing to 22.39x forward earnings implies the market expects meaningful earnings growth over the next twelve months, and the PEG ratio of 14.62 suggests that growth alone does not fully justify the price on a conventional basis. The EV/EBITDA of 24.29 versus a forward 15.25 reinforces this expectation of rapid earnings expansion. Investors should monitor whether reported margin gains materialize, since the multiple depends heavily on that trajectory rather than on current earnings power.

Operating Margin Recovery Remains Uneven

As reported in financial statements, NBIX's operating margin swung from 4.1% in 2025Q1 to 30.1% in 2025Q3 and settled at 29.5% in 2026Q3, while gross margin held stably between 97.6% and 98.7%.

With gross margin near saturation, the operating margin is the more informative indicator of earning power, and its oscillation implies that operating expenses or non-recurring items shift materially from quarter to quarter. The 2026Q3 net margin of 18.4% trails the 26.4% reached in 2025Q3, suggesting below-the-line items may be weighing on reported earnings. The pattern warrants further investigation into the drivers of quarterly expense volatility before treating the latest margin as sustainable.

Returns Recovering but Still Modest

Based on NBIX's reported figures, ROIC rose from 0.6% in 2025Q1 to 6.2% in 2026Q3, yet remains low relative to the 14.2% ROIC reported by INVA and suggests the capital base is still being redeployed.

The improvement in ROIC appears driven primarily by operating margin recovery rather than by asset efficiency, since asset turnover has remained near 0.20. ROE of 5.2% in the latest quarter is constrained by an equity base that has been reduced by buybacks, which may partially mask underlying capital productivity. Returns that are compounding from a low base are encouraging, but the absolute level does not yet indicate a high-return franchise.

Low Leverage with Episodic Debt Spikes

According to the reported ratio data, NBIX's debt-to-equity has remained near 0.10 in recent quarters, spiking to 0.30 in 2025Q3 before retreating, while interest coverage has fluctuated between roughly 1.05x and 14.34x.

A debt-to-equity ratio near 0.10 indicates limited reliance on borrowing, and the subsequent retreat from the 2025Q3 spike suggests debt was repaid rather than refinanced. The volatility in interest coverage, however, reflects swings in operating income rather than a structural debt burden, so the coverage figures should be read cautiously. Refinancing risk appears low based on the reported figures, though the data does not disclose covenant terms, which should be checked directly in the filings.

Liquidity Cushion Narrowing from Peak

As reported in financial statements, NBIX's current ratio declined from 4.37 in 2024Q3 to 2.04 in 2026Q3, while quick ratio followed a similar path to 1.97, still comfortably above one.

The compression in current and quick ratios reflects both a rise in current liabilities and a decline in the relative weight of liquid assets, rather than any sign of stress. Quick ratios remaining close to current ratios indicate that inventory is a minor component of current assets, consistent with a pharmaceutical business relying on receivables and cash. The position remains well above typical stress thresholds, though the downward trend merits monitoring as the company deploys capital.

Misapplied P/E Obscures Cash Economics

Based on reported figures, the P/E ratio is the most commonly misapplied metric for NBIX, since stock-based compensation and goodwill-related items can distort reported earnings relative to cash generation.

P/E is often used as the primary valuation anchor, yet NBIX's net income has diverged materially from operating income in several quarters, making trailing earnings a noisy basis for comparison. Free cash flow yield, measured through the P/FCF of 21.46, and EV-based multiples provide a more stable reference by neutralizing non-operating items and capital structure effects. Investors should prioritize FCF-based metrics and adjust for stock-based compensation when assessing whether the valuation premium is justified.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open NBIX Terminal

NBIX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NBIX — Frequently Asked Questions

Quick answers to the most common questions about buying NBIX stock.

What is Neurocrine Biosciences, Inc.'s P/E ratio?

Neurocrine Biosciences, Inc.'s current P/E ratio is 24.8x. The historical average is 48.6x. This places it at the 20th percentile of its historical range.

What is Neurocrine Biosciences, Inc.'s EV/EBITDA?

Neurocrine Biosciences, Inc.'s current EV/EBITDA is 17.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 43.8x.

What is Neurocrine Biosciences, Inc.'s ROE?

Neurocrine Biosciences, Inc.'s return on equity (ROE) is 16.4%. The historical average is -21.7%.

Is NBIX stock overvalued?

Based on historical data, Neurocrine Biosciences, Inc. is trading at a P/E of 24.8x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Neurocrine Biosciences, Inc.'s profit margins?

Neurocrine Biosciences, Inc. has 98.2% gross margin and 21.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Neurocrine Biosciences, Inc. have?

Neurocrine Biosciences, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.